Accessibility Menu
 
Navidea Biopharmaceuticals logo

Navidea Biopharmaceuticals

(OTC) NAVB

Current PriceN/A
Market CapN/A
Since IPO (1992)-100%
5 Year-100%
1 Year-100%
1 Month+0%

Navidea Biopharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$610.00

Net Income (TTM)

$1.18M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

NAVB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Navidea Biopharmaceuticals

Industry

Biotechnology

Employees

15

CEO

Michael S. Rosol, PhD

Headquarters

Dublin, OH 43017-3552, US

NAVB Financials

Key Financial Metrics (TTM)

Gross Margin

-3%

Operating Margin

-214%

Net Income Margin

-231%

Return on Equity

4%

Return on Capital

3%

Return on Assets

-3%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Short Interest

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$170.30K

Operating Income

$14.05M

EBITDA

$13.98M

Operating Cash Flow

$8.99M

Capital Expenditure

$390.35K

Free Cash Flow

$9.38M

Cash & ST Invst.

$2.00M

Total Debt

$2.44M

Navidea Biopharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$36.03K

+71.6%

Gross Margin

0.00%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

11

N/A

Net Income

$2.26M

+60.5%

EBITDA

$2.10M

+62.3%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Net Cash

$2.61M

-6.3%

Accounts Receivable

$30.87K

-80.1%

Inventory

$460.75K

+137.7%

Long Term Debt

$269.00

-100.0%

Short Term Debt

$1.26M

+2202.9%

Return on Assets

-3.47%

N/A

Return on Invested Capital

2.52%

N/A

Free Cash Flow

$10.27M

-430.0%

Operating Cash Flow

$10.25M

-451.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNBTGenerex Biotechnology Corporation
$0.00+0.00%
WPDPFWPD Pharmaceuticals Inc.
$0.00+0.00%
NNMXNanomix Corporation
$0.00+0.00%
NMDBFNeonMind Biosciences Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$174.36+0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$41.68+0.10%
APLSApellis Pharmaceuticals
$40.24+1.35%
TSLATesla
$371.35+0.05%

Questions About NAVB

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.